Recent Updates
Recently added Catalysts
MYO Positive Sentiment

Myomo Reports Third Quarter 2025 Financial and Operating Results

Monday, November 10, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Myomo, Inc. reported its financial results for Q3 2025, achieving a revenue of $10.1 million. The company noted 229 authorizations and orders, marking its highest count for the year. Myomo also reiterated its full-year revenue guidance, projecting between $40 million and $42 million. A conference call is scheduled for today at 4:30 PM Eastern time.
Price reaction · baseline $0.8619 (2025-11-10T16:04:00.000Z) · hit during market hours · clean, no other MYO news in the window
day 0 close · peak
+6.4%
day 1
-1.4%
day 3
-6.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue of $10.1 million indicates strong financial performance.
  • 229 authorizations and orders represent the highest number this year.
  • The company reaffirms its revenue guidance of $40 million to $42 million.

Full Press Release Details

Revenue of $10.1 million
229 authorizations and orders, highest number this year
Reiterates full year revenue guidance of $40 million to $42 million
Conference call begins today at 4:30pm Eastern time
BURLINGTON, Mass. (November 10, 2025) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. Read more.

Frequently Asked Questions

What was Myomo's revenue for Q3 2025?

Myomo reported a revenue of $10.1 million for Q3 2025.

How many authorizations and orders did Myomo have?

Myomo had 229 authorizations and orders, the highest this year.

What is Myomo's revenue guidance for the full year?

Myomo reiterated its revenue guidance of $40 million to $42 million.

When is Myomo's conference call scheduled?

The conference call is scheduled for today at 4:30 PM Eastern time.

ShareAdd on Google
Tags: MYO Viatris Investor Conferences Healthcare Myomo financial results revenue guidance medical robotics
Last updated: Nov 10, 2025

Biotech snapshot

Cash runway
$13M liquidity · $1M/mo burn
~20 mo
Low dilution risk